Financial Data and Key Metrics Changes - The company recorded net product sales of approximately $8.8 million in Q1 2025, reflecting an 18% growth compared to $7.4 million in Q1 2024 and an 11% increase over Q4 2024 [15][16] - Selling and marketing expenses decreased to $2.9 million in Q1 2025 from $5.2 million in Q1 2024, primarily due to the elimination of European pre-commercialization expenses [17] - General and administrative expenses were $6.1 million in Q1 2025, consistent year-over-year but increased from $4.1 million in Q4 2024 [18] - Cash and cash equivalents stood at $22.6 million as of March 31, 2025, with a cash burn of approximately $4 million in Q1 2025 [18] Business Line Data and Key Metrics Changes - The company has made significant progress in targeting prescribers for Pedmark, particularly in the adolescent and young adult (AYA) patient population, which is expected to have a larger market potential than the pediatric market [9][10] - The targeting model implemented has shown early traction, with tier one targets prescribing Pedmark and integrating it into treatment plans [7][10] Market Data and Key Metrics Changes - The AYA segment is estimated to have approximately 20,000 cisplatin chemotherapy patients treated annually in the U.S., with a favorable reimbursement profile [9] - The product has launched commercially in Germany and the UK, with recent acceptance for use in Scotland [12] Company Strategy and Development Direction - The company is focused on enhancing field execution and supporting sustainable growth across key segments, particularly through a data-driven targeting model [5][6] - There is a strategic emphasis on deepening relationships with key accounts and expanding adoption among existing customers [14] - The company is exploring additional strategic opportunities in oncology supportive care, with ongoing discussions about potential synergies [66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, anticipating significant quarterly growth in net product sales as foundational initiatives take effect [17] - The company remains optimistic about the impact of its strategic focus and disciplined execution, expecting continued progress throughout the year [14][71] Other Important Information - The company does not anticipate that proposed tariffs will materially impact gross margins or overall financial performance, as Pedmark is manufactured in the U.S. [19] Q&A Session Summary Question: Average number of vials per patient and adherence rates - The average is about 30 vials per patient, with approximately 50% adherence to the full treatment course [21][23] Question: Improvements in the FENICHERS program - The program has been redesigned to enhance home administration capabilities, which is critical for improving adherence [26][27] Question: Operating expenses and future revenue expectations - Operating expenses are expected to be front-end loaded, with a potential decrease in the second half of the year [30][31] - The company aims for revenue growth to reach breakeven, targeting approximately $8.5 to $9 million in sales [47][48] Question: Expansion into ex-U.S. markets - The company is focusing on major European markets, with Spain, Italy, and France as potential future opportunities for Pedmark [62][63] Question: Strategic opportunities in oncology supportive care - The company is open to exploring strategic opportunities and partnerships that could enhance its offerings in supportive care [66]